查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000722

疫苗输送装置市场：依装置类型、给药途径、产品形式及最终用户划分－2026-2032年全球市场预测

Vaccine Delivery Devices Market by Device Type, Administration Route, Product Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疫苗输送设备市场价值将达到 84.3 亿美元，到 2026 年将成长至 93.2 亿美元，到 2032 年将达到 172.5 亿美元，年复合成长率为 10.77%。

主要市场统计数据
基准年 2025 84.3亿美元
预计年份：2026年 93.2亿美元
预测年份 2032 172.5亿美元
复合年增长率 (%) 10.77%

对多方面的疫苗输送设备市场进行策略性展望，重点在于临床需求、技术进步、供应链复杂性和数位化整合。

疫苗输送装置产业处于临床需求、技术创新和复杂法律规范的交汇点。近年来，我们见证了疫苗传输装置从纯粹的机械式一次性产品转变为整合系统，后者融合了人体工学、互联性、低温运输相容性和用户安全性等要素。这项转变受到双重压力的驱动：一是免疫接种计画的扩展，二是治疗性生物製药日益复杂，需要精准给药、确保低温运输完整性并监测用药依从性。

数位连接、人性化的安全、模组化製造、监管清晰和供应链韧性的融合正在改变疫苗输送设备的格局。

多项变革正在重塑疫苗输送装置的设计、製造、监管和部署方式。首先，数位化整合和连网型设备的成熟正在改变人们对接种后监测、用药依从性分析和远端临床监测的预期。这一趋势不仅限于基本的连接，还包括安全的数据处理、设备认证以及分析输出，这些输出都能为个别患者照护和人群免疫策略提供资讯。

评估 2025 年实施的关税措施如何重塑整个生态系统的供应链采购决策、采购架构和设备开发重点。

2025年实施的关税措施影响了美国的进出口贸易，对製造商、供应商和医疗保健机构产生了一系列累积影响。这些关税措施提高了许多医疗设备类别中使用的进口零件的相对成本，立即给筹资策略带来压力，并促使人们重新评估全球供应商基础。对于依赖海外精密模塑塑胶零件、电子感测器或灭菌服务的医疗设备而言，关税负担正在加速关于本地生产和双重采购安排的讨论。

从医疗设备类型、给药途径、最终用户环境和製剂形式等方面进行详细的观点，为策略性定位提供指南。

深入了解市场区隔对于使产品策略与临床和商业性实际情况相符至关重要。从医疗设备类型来看，市场包括自动注射器、输液帮浦、喷射注射器、笔式註射器、预填充式注射器和安全注射器。自动注射器包括一次性使用装置和可重复使用平台，后者又可细分为电子式和机械式，两者对生命週期成本、训练负担和资料收集的影响各不相同。输液帮浦涵盖弹性体、注射器和容积式三种类型，其中容积式输液帮浦可细分为携带式和固定式系统，以适应不同的护理环境和剂量需求。

美洲、欧洲、中东和非洲以及亚太地区的区域差异和采用趋势会影响设备选择、製造和采购。

区域趋势持续以不同的方式影响技术应用、监管合规和供应商关係。在美洲，采购模式和大规模免疫接种计画正在推动对兼顾单位效率和安全性的设备的需求。此外，能够与免疫接种登记系统和电子健康记录整合的连网型设备也越来越受到关注。该地区关于近岸外包和扩大生产规模以应对全球供应链中断的讨论也在不断升温。

企业平台策略、策略联盟、监管因应措施和服务模式如何重新定义医疗设备製造商的竞争优势。

主要企业的竞争与合作正以多种可预见的方式塑造疫苗输送装置的演变。领先的製造商正投资于平台策略，使其能够在多个治疗领域扩展装置功能，同时分摊研发和监管成本。装置公司与生技药品研发公司之间的合作日益普遍，这反映出在研发早期阶段检验装置与药物的兼容性以及设计整合式患者支援方案的必要性。

为医疗设备製造商和医疗保健提供者提供切实可行的策略措施，以增强韧性、加快部署，并在所有医疗保健环境中提供永续价值。

产业领导企业应采取多管齐下的策略，兼顾短期韧性和长期创新。首先，应实现供应商组合多元化，投资关键零件的双重采购，并评估近岸外包机会，以降低关税波动和物流中断带来的风险。其次，应优先发展模组化产品平台，实现一次性组件和可重复使用组件之间的快速重构，并在设计时充分考虑与数位医疗生态系统的互通性，从而提升临床价值。

为了检验我们的见解，我们采用了一种综合性的混合研究途径，结合了初步访谈、监管和专利审查、供应链映射和情境分析。

本研究整合了多种资料流，以得出可靠且基于证据的结论。初步调查包括对医疗设备工程师、医院和门诊临床负责人、采购负责人以及监管专家进行结构化访谈，以收集有关器械性能、易用性和供应限制的第一手资讯。专家研讨会和咨询委员会则提供了关于临床工作流程解读以及临床医生在选择不同给药途径或产品形式的器械时面临的实际权衡的见解。

整合策略挑战，展示技术、法规、市场区隔和供应弹性应如何整合，以提供有效的疫苗交付解决方案。

疫苗输送装置的格局正经历着一场精心策划的变革，其驱动力来自不断发展的技术能力、监管环境的变化以及人们对安全性和供应稳定性的日益增长的期望。装置创新不仅因其产品本身的特性而备受重视，更因其能够显着改善临床工作流程、提高依从率和增强系统整体可靠性而受到关注。供应链和贸易趋势正在加速策略转型，包括供应商多元化、模组化生产方式以及重新聚焦于能够带来营运优势的区域生产能力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：疫苗输送装置市场：依装置类型划分

  • 自动注射器
    • 一次性自动注射器
    • 可重复使用的电子自动注射器
    • 机械式可重复使用汽车喷油器
  • 点滴帮浦
    • 弹性体泵
    • 注射式帮浦
    • 容积式泵
      • 携带式容积泵
      • 固定式容积泵
  • 喷射注射器
  • 无针注射器
    • 液体注射器
    • 粉末注射器
  • 笔式註射器
    • 一次性笔式註射器
    • 可重复使用的笔式註射器
      • 电子可重复使用笔式註射器
      • 机械式可重复使用笔型注射器
  • 预填充式注射器

第九章：依给药途径分類的疫苗给药装置市场

  • 皮内注射
  • 肌肉内注射
  • 静脉注射
  • 黏膜给药
    • 鼻腔给药
    • 口服
  • 皮下注射

第十章：疫苗输送装置市场：依产品类型划分

  • 液体
  • 冷冻干燥製剂

第十一章：疫苗输送装置市场：依最终用户划分

  • 门诊部
  • 诊所
    • 基层医疗诊所
    • 专科诊所
  • 居家医疗
  • 医院

第十二章：疫苗输送装置市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：疫苗输送装置市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：疫苗输送装置市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国疫苗输送装置市场

第十六章：中国疫苗注射器材市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • AptarGroup, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Catalent, Inc.
  • Consort Medical plc
  • Elcam Medical
  • Gerresheimer AG
  • Inovio Pharmaceuticals, Inc.
  • Nipro Corporation
  • PharmaJet, Inc.
  • SCHOTT AG
  • Stevanato Group SpA
  • Terumo Corporation
  • Vaxxas Pty Ltd
  • Vetter Pharma International GmbH
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG
Product Code: MRR-02026C4C8C99

The Vaccine Delivery Devices Market was valued at USD 8.43 billion in 2025 and is projected to grow to USD 9.32 billion in 2026, with a CAGR of 10.77%, reaching USD 17.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.43 billion
Estimated Year [2026] USD 9.32 billion
Forecast Year [2032] USD 17.25 billion
CAGR (%) 10.77%

A strategic orientation to the multifaceted vaccine delivery device landscape highlighting clinical needs, engineering evolution, supply chain complexity, and digital integration

The vaccine delivery device field sits at the intersection of clinical need, engineering innovation, and complex regulatory oversight. Recent years have seen a shift from purely mechanical disposables toward integrated systems that combine ergonomics, connectivity, cold chain compatibility, and user safety. This evolution is driven by the dual pressures of expanding immunization programs and the increasing complexity of therapeutic biologics that demand precise dosing, cold chain integrity, and adherence monitoring.

Clinical stakeholders and procurement teams are adapting to an environment where device selection is no longer driven solely by unit cost but by total cost of administration, patient adherence, and lifecycle safety. Manufacturers are responding by investing in design for manufacturability, human factors engineering, and regulatory strategy to support quicker clinical adoption. Meanwhile, healthcare providers require devices that address a range of administration routes and site-of-care constraints, from high-throughput hospital vaccination clinics to home-based administration for chronic therapies.

Given the breadth of device types-from auto-injectors and infusion pumps to needle-free injectors and prefilled syringes-stakeholders must evaluate trade-offs across usability, sterility assurance, compatibility with formulation formats, and environmental footprint. These considerations are increasingly evaluated alongside digital features such as dose tracking, connectivity for adherence programs, and interoperability with electronic health records. As the market matures, the ability to align device selection with clinical protocols, supply chain realities, and patient behavior will be a key determinant of successful deployment.

Converging forces of digital connectivity, human-centered safety, modular manufacturing, regulatory clarity, and supply chain resilience transforming vaccine delivery device dynamics

Multiple transformative shifts are reshaping how vaccine delivery devices are designed, manufactured, regulated, and adopted. First, digital integration and the maturation of connected devices are changing expectations for post-administration monitoring, adherence analytics, and remote clinical oversight. This trend extends beyond basic connectivity to include secure data handling, device authentication, and analytics-ready outputs that inform both individual patient care and population-level immunization strategies.

Second, human-centered design and a renewed focus on safety have elevated preferences for devices that reduce needle-stick risk and improve ease-of-use for non-specialist administrators. This has accelerated interest in needle-free technologies, safety-engineered syringes, and auto-injectors that prioritize intuitive operation under stress. Third, manufacturing strategies are shifting toward modular and flexible platforms that can accommodate multiple device formats and formulation types, enabling faster configuration for emergent needs.

Fourth, regulatory environments are converging around clearer expectations for combination products, cybersecurity for connected devices, and real-world evidence to support post-market surveillance. This regulatory clarity is prompting manufacturers to embed compliance considerations earlier in the development process. Fifth, supply chain resilience and nearshoring are gaining prominence, with organizations re-evaluating supplier concentration, component sourcing, and sterilization capacity to reduce geopolitical and logistic risk. Together, these shifts are creating a landscape in which technological capability, regulatory foresight, and supply chain agility determine which products achieve durable clinical uptake.

Assessment of how tariff measures implemented in 2025 have reshaped supply chain sourcing decisions, procurement frameworks, and device development priorities across the ecosystem

The introduction of tariffs in 2025 affecting trade flows into and out of the United States has produced a set of cumulative impacts that ripple across manufacturers, suppliers, and healthcare providers. Tariff measures have increased the relative cost of imported components used in many device categories, creating immediate pressure on procurement strategies and inducing a re-evaluation of the global supplier base. For devices that rely on precision-molded plastic components, electronic sensors, or sterilization services sourced internationally, the tariff burden has accelerated conversations about local manufacturing or dual-sourcing arrangements.

This dynamic has particular implications for disposable-heavy supply chains where recurring purchases amplify the cost impact. Manufacturers and health systems have had to reconcile the trade-off between short-term price increases and the long-term benefits of onshore capacity such as reduced logistics risk and improved supply continuity. For product development, higher component costs have prompted design-for-cost reviews and, in some cases, product simplification to protect margins while preserving safety and regulatory compliance.

Procurement teams are adapting contract structures and hedging strategies to mitigate volatility, while manufacturers are engaging more closely with tier-one suppliers to identify cost-reduction pathways that do not compromise sterility assurance or performance. At the same time, there is evidence of increased collaboration between device makers and formulation partners to optimize device-drug compatibility and reduce total system costs. The cumulative effect of tariffs has therefore been to accelerate existing trends toward supply chain diversification, localized manufacturing, and closer alignment between device design choices and procurement realities.

In-depth segmentation perspective that connects device typologies, administration pathways, end-user environments, and formulation formats to inform strategic positioning

A granular understanding of segmentation is essential for aligning product strategy with clinical and commercial realities. When viewed through the lens of device type, the landscape comprises auto-injectors, infusion pumps, jet injectors, needle-free injectors, pen injectors, prefilled syringes, and safety syringes. Within auto-injectors, there are disposable devices as well as reusable platforms that divide into electronic and mechanical subtypes, each with distinct implications for lifecycle costs, training burden, and data capture. Infusion pumps span elastomeric, syringe-based, and volumetric approaches, with volumetric options further characterized by ambulatory and floor-mounted systems that serve different care settings and administration volumes.

Jet injectors differentiate between multi-use nozzle architectures and single-use nozzle formats, while needle-free injectors split into liquid and powder delivery modalities; liquid systems further segment into electric, gas-based, and spring-based mechanisms that entail varied power and maintenance considerations. Pen injectors offer disposable and reusable choices, and among reusables there is a split between electronic and mechanical innovators that alter dosing precision and integration potential. Prefilled syringes are available in glass or plastic constructions, with plastic variants subdividing into external needle and integrated needle configurations that influence ease-of-use and disposal practices. Safety syringes come in both active and passive safety implementations, each designed to reduce sharps injuries and support compliance with occupational safety requirements.

Administration route is a complementary axis of segmentation, encompassing intradermal, intramuscular, intravenous, mucosal, and subcutaneous approaches. Mucosal delivery further bifurcates into nasal and oral pathways, each presenting unique formulation and device interface challenges. End-user contexts include ambulatory care centers, clinics, home healthcare, and hospitals; within clinics, the needs of primary care and specialty clinics diverge based on throughput, staff expertise, and therapeutic focus. Product form is another critical discriminator, with liquid and lyophilized formulations presenting different handling, reconstitution, and device compatibility requirements. Both liquid and lyophilized families can be packaged in multi-dose or single-dose vials, and those choices influence device selection, waste management, and cold chain logistics. An integrated segmentation strategy that aligns device type, administration route, end-user setting, and product form is therefore essential to matching solution capabilities with clinical workflows and procurement constraints.

Regional contrasts and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence device selection, manufacturing, and procurement

Regional dynamics continue to shape technology adoption, regulatory pathways, and supplier relationships in distinct ways. In the Americas, procurement models and large immunization programs create demand for devices that balance unit efficiency with safety, and there is growing traction for connected devices that can integrate with immunization registries and electronic medical records. This region also exhibits accelerated conversations about nearshoring and manufacturing scale-up to buffer against global supply interruptions.

Across Europe, Middle East & Africa, regulatory convergence and emphasis on patient safety drive interest in safety-engineered syringes and needle-free alternatives, while divergent procurement capacities produce a spectrum of adoption rates and device preferences. In high-income markets within this region, digital integration and lifecycle service offerings are becoming differentiators, whereas in resource-constrained settings the emphasis remains on simplicity, robustness, and cold chain efficiency.

Asia-Pacific presents a heterogeneous mix of rapid industrial capability, domestic manufacturing ambitions, and varied regulatory regimes. Several markets in this region are scaling local production capacity for both devices and formulation fill-finish, and there is strong interest in cost-effective disposable platforms as well as innovative needle-free technologies that can support mass immunization campaigns. Across all regions, differences in clinical practice, reimbursement models, and supply chain architecture mean that a one-size-fits-all device strategy is unlikely to succeed; instead, regionalized product adaptations and partnerships are needed to achieve both clinical and commercial objectives.

How corporate platform strategies, strategic alliances, regulatory positioning, and service models are redefining competitive advantage among device manufacturers

The competitive and collaborative behavior of key companies is shaping the evolution of vaccine delivery devices in several predictable ways. Leading manufacturers are investing in platform strategies that allow them to extend device functionality across multiple therapeutic areas while amortizing development and regulatory costs. Partnerships between device firms and biologics developers are increasingly common, reflecting the need to validate device-drug compatibility early in development and to design integrated patient support programs.

Supply-side consolidation and strategic alliances are visible where sterilization capacity, component supply, and high-volume assembly create barriers to rapid scaling. At the same time, smaller innovators are driving niche advances in needle-free technologies, micro-dosing, and digital adherence tools that incumbents may choose to acquire or integrate through licensing. Regulatory approvals and clearance pathways remain central competitive battlegrounds, and companies that demonstrate robust human factors testing, cybersecurity assurances, and post-market evidence generation can more readily secure health-system adoption.

Service models-ranging from device-as-a-service to full lifecycle support contracts that include training, maintenance, and data analytics-are emerging as differentiators that influence procurement decisions. Companies that are able to couple product quality with dependable supply and responsive service will command stronger positioning, particularly in markets where operational continuity and clinical outcomes are closely scrutinized.

Practical strategic moves for device manufacturers and health providers to enhance resilience, accelerate adoption, and capture sustained value across care settings

Industry leaders should adopt a multi-pronged strategy that balances short-term resilience with long-term innovation. First, diversify supplier portfolios and invest in dual-sourcing for critical components while evaluating nearshoring opportunities to reduce exposure to tariff volatility and logistic disruption. Second, prioritize modular product platforms that allow rapid reconfiguration between disposable and reusable elements, and design for interoperability with digital health ecosystems to extend clinical value.

Third, embed regulatory strategy and human factors engineering early in the development lifecycle to reduce time-to-adoption risk and to support clear labeling and post-market surveillance plans. Fourth, pursue partnerships with formulation developers to ensure device-drug compatibility is optimized for both liquid and lyophilized presentations, and adapt device interfaces to the practical needs of primary care, specialty clinics, hospitals, ambulatory centers, and home healthcare settings. Fifth, consider services that go beyond the device itself-training, maintenance, data analytics, and lifecycle management-to create differentiated procurement propositions that lower total cost of administration and improve clinical adherence.

Finally, embrace evidence generation that demonstrates real-world performance, safety, and user preference. Operational pilots, pragmatic usability studies, and registry data can accelerate payer and provider acceptance. By aligning product design with procurement realities and clinical workflows, industry leaders can reduce adoption friction and create durable pathways to scale.

Comprehensive mixed-methods research approach combining primary interviews, regulatory and patent review, supply chain mapping, and scenario analysis to validate insights

This research synthesizes diverse data streams to ensure robust, evidence-based conclusions. Primary research included structured interviews with device engineers, clinical leaders across hospital and ambulatory settings, procurement officers, and regulatory experts to capture experiential insights on device performance, usability, and supply constraints. Expert workshops and advisory panels informed interpretations of clinical workflows and the practical trade-offs clinicians face when selecting devices for different administration routes and product forms.

Secondary research encompassed public regulatory filings, guidance documents, patent literature, manufacturer technical specifications, and peer-reviewed clinical studies to validate design claims and safety profiles. Supply chain mapping combined vendor disclosures, logistics data, and trade flow analysis to identify concentration risks and potential resiliency strategies. Where appropriate, human factors and usability testing reports were reviewed to assess user error risks and training needs.

Analytic approaches included cross-validation of qualitative findings with documentary evidence, scenario stress-testing of supply chain responses to tariff and disruption events, and thematic synthesis of technology adoption drivers. Care was taken to triangulate claims from manufacturers with independent clinical and procurement perspectives to deliver balanced, actionable insights. Limitations of the research were mitigated by seeking multiple sources for critical assertions and by documenting areas where data scarcity requires cautious interpretation.

Synthesis of strategic imperatives showing how technology, regulation, segmentation, and supply resilience must converge to enable effective vaccine delivery solutions

The vaccine delivery device landscape is undergoing a period of purposeful transformation driven by technological capability, regulatory evolution, and heightened expectations around safety and supply resilience. Device innovation is increasingly judged by its ability to deliver measurable improvements in clinical workflows, adherence, and total system reliability rather than by discrete product features alone. Supply chain and trade dynamics have accelerated strategic shifts such as diversification of suppliers, modular manufacturing approaches, and a renewed emphasis on localized capacity where it delivers operational advantages.

Segmentation across device types, administration routes, end-user settings, and formulation formats remains essential for matching solution attributes to practical use cases. Regional differences underscore the need for adaptable strategies that consider procurement mechanisms, regulatory regimes, and infrastructure constraints. Companies that marry robust product engineering with thoughtful regulatory planning, service-oriented business models, and targeted evidence generation will be best positioned to secure durable adoption. The path forward requires coordinated action across design, manufacturing, and commercial functions to translate promising technologies into sustainable improvements in vaccine delivery and public health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Delivery Devices Market, by Device Type

  • 8.1. Auto-Injectors
    • 8.1.1. Disposable Auto-Injectors
    • 8.1.2. Electronic Reusable Auto-Injectors
    • 8.1.3. Mechanical Reusable Auto-Injectors
  • 8.2. Infusion Pumps
    • 8.2.1. Elastomeric Pumps
    • 8.2.2. Syringe Pumps
    • 8.2.3. Volumetric Pumps
      • 8.2.3.1. Ambulatory Volumetric Pumps
      • 8.2.3.2. Floor-Mounted Volumetric Pumps
  • 8.3. Jet Injectors
  • 8.4. Needle-Free Injectors
    • 8.4.1. Liquid Injectors
    • 8.4.2. Powder Injectors
  • 8.5. Pen Injectors
    • 8.5.1. Disposable Pen Injectors
    • 8.5.2. Reusable Pen Injectors
      • 8.5.2.1. Electronic Reusable Pen Injectors
      • 8.5.2.2. Mechanical Reusable Pen Injectors
  • 8.6. Prefilled Syringes

9. Vaccine Delivery Devices Market, by Administration Route

  • 9.1. Intradermal Injection
  • 9.2. Intramuscular Injection
  • 9.3. Intravenous Injection
  • 9.4. Mucosal Delivery
    • 9.4.1. Nasal Delivery
    • 9.4.2. Oral Delivery
  • 9.5. Subcutaneous Injection

10. Vaccine Delivery Devices Market, by Product Form

  • 10.1. Liquid Formulations
  • 10.2. Lyophilized Formulations

11. Vaccine Delivery Devices Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals

12. Vaccine Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Delivery Devices Market

16. China Vaccine Delivery Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. AptarGroup, Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Becton, Dickinson and Company
  • 17.9. Catalent, Inc.
  • 17.10. Consort Medical plc
  • 17.11. Elcam Medical
  • 17.12. Gerresheimer AG
  • 17.13. Inovio Pharmaceuticals, Inc.
  • 17.14. Nipro Corporation
  • 17.15. PharmaJet, Inc.
  • 17.16. SCHOTT AG
  • 17.17. Stevanato Group S.p.A.
  • 17.18. Terumo Corporation
  • 17.19. Vaxxas Pty Ltd
  • 17.20. Vetter Pharma International GmbH
  • 17.21. West Pharmaceutical Services, Inc.
  • 17.22. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 288. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 301. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES VACCINE DELIVE